SCHEMBL17050409

SCHEMBL17050409

CCN1Cc2c(cncc2C(C)C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 11/20 0.41
HSP90AB1 P08238 1/20 0.39
UGCG Q16739 1/20 0.31
LRRK2 Q5S007 1/20 0.31
DHPS P49366 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19984501 0.80 IDH1 (0.40) IDH1UGCGLRRK2DHPS
SCHEMBL20820768 0.80 IDH1 (0.38) IDH1UGCGLRRK2DHPS
SCHEMBL17050405 0.77 IDH1 (0.47) IDH1HSP90AB1DHPS
SCHEMBL20820769 0.76 IDH1 (0.36) IDH1UGCGLRRK2DHPS
SCHEMBL799362 0.76 HSP90AB1 (0.41) IDH1HSP90AB1
SCHEMBL21004803 0.69 IDH1 (0.57) IDH1HSP90AB1LRRK2
SCHEMBL25961893 0.67 IDH1 (0.43) IDH1HSP90AB1
SCHEMBL20933060 0.66 CRBN (0.53)
SCHEMBL23228512 0.65 IDH1 (0.53) IDH1UGCGLRRK2
SCHEMBL23350137 0.64 MAPK1 (0.48) IDH1LRRK2DHPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180079727-A1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO., LTD. (JP) 2018-03-22 US disclosed
US-20180079727-A1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO., LTD. (JP) 2018-03-22 US disclosed
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2016-09-08 US disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079727-A1 9-MEMBERED FUSED RING DERIVATIVE ACSS2, AGTR2, ACSL3 IDH1 129/4885HSP90AB1 4416/4885UGCG 3267/4885
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE ACSS2, ACACB, ACAT2 IDH1 587/4885HSP90AB1 3034/4885UGCG 2525/4885
US-20160257641-A1 NOVEL ALKYLENE DERIVATIVES ACSS2, ACACB, ADCY2 IDH1 487/4885HSP90AB1 4373/4885UGCG 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.